Verve is developing drug candidates for heart disease, including the PCSK9-targeted VERVE-102, a base-editing therapy.

The project will leverage Noetik's AI model and multimodal spatial data to search for biomarkers of patient response to Agenus' immunotherapy regimen.

The firm will assess irpagratinib plus best supportive care in patients with FGF19-overexpressing advanced liver cancer.